




CERTIFIED REFERENCE MATERIAL CERTIFICATE OF ANALYSIS

NMIA D614: 7 α , 17 α -Dimethyl-5 β -androstane-3 α , 17 β -diol

Report ID: D614.2019.01 (Ampouled 080901)

Chemical Formula: C₂₁H₃₆O₂

Molecular Weight: 320.5 g/mol



Certified value

Batch No.	CAS No.	Mass per ampoule
99-S-27	13611-10-4	992 ± 14 µg

The uncertainty has been calculated according to ISO Guide 35 and is stated at the 95% confidence limit (k = 2).

IUPAC name: (3 α ,5 β ,7 α ,17 β)-7,17-Dimethylandrostane-3,17-diol (Metabolite of bolasterone)

Expiration of certification: The property values are valid till 12 June 2024, i.e. five years from the date of re-certification provided the **unopened** material is handled and stored in accordance with the recommendations below. The material as issued in the unopened container and stored as recommended below should be suitable for use beyond this date, subject to confirmation of batch stability from the issuing body. The expiry date/shelf life does not apply to ampoules that have been opened. In such cases it is recommended that the end-user conduct their own in-house stability trials.

Description: The compound is supplied as a dried aliquot in a sealed ampoule and is intended for a single use to prepare a standard solution containing D614. Material sourced from an external supplier, and certified for identity and purity by NMIA.

Intended use: This certified reference material is suitable for use as a primary calibrator.

Instructions for use: Open the ampoule and carefully rinse the interior at least three times with a suitable organic solvent (e.g. chloroform). This will transfer 992 ± 14 µg of anhydrous 7 α , 17 α -dimethyl-5 β -androstane-3 α , 17 β -diol.

Recommended storage: When not in use, this material should be stored at or below 4 °C in a closed container in a dry, dark area.

Metrological traceability: The certified purity value is traceable to the SI unit for mass (kg) through Australian national standards via balance calibration. In the mass balance approach all impurities are quantified as a mass fraction and subtracted from 100%.

Stability: This material has demonstrated stability over a minimum period of five years. The measurement uncertainty at the 95% confidence interval includes a stability component which has been estimated from annual stability trials. The long-term stability of the compound in solution has not been examined.

Homogeneity assessment: The homogeneity of the material was assessed using purity assay by GC-FID on five randomly selected ampoules of the material. The material was judged to be sufficiently homogeneous at this level of sampling as the variation in analysis results between samples was not significantly different at a 95% confidence level from that observed on repeat analysis of the same sample.

Safety: Treat as hazardous substance. Use appropriate work practices when handling to avoid skin or eye contact, ingestion or inhalation of dust. Refer to the provided safety data sheet.

S. R. Davies

Dr Stephen R. Davies,
Team Leader,
Chemical Reference Materials, NMI.
18 June 2019

This report supersedes any issued prior to 18 June 2019

NATA logo notice: Accredited for compliance with ISO 17034. Accreditation No. 198 / Corporate Site No. 20844. The results of the tests, calibrations and/or measurements included in this document are traceable to Australian/national standards.

Legal notice: Terms and Conditions associated with the provision of this reference material can be found on the NMIA website.

Characterisation Report:

GC-FID:	Instrument:	Agilent 6890N
	Column:	HP-1 Capillary, 30 m \times 0.32 mm I.D. \times 0.25 μ m
	Program:	180 $^{\circ}$ C (1 min), 10 $^{\circ}$ C/min to 240 $^{\circ}$ C (5 min), 30 $^{\circ}$ C/min to 300 $^{\circ}$ C (3 min)
	Injector:	250 $^{\circ}$ C
	Detector Temp:	320 $^{\circ}$ C
	Carrier:	Helium
	Split ratio:	20/1
	Relative mass fraction of the main component:	
	Initial analysis:	Mean = 99.2%, s = 0.004% (7 ampoules in duplicate, September 2008)
	Re-analysis:	Mean = 99.2%, s = 0.05% (5 ampoules in duplicate, September 2009)
	Re-analysis:	Mean = 99.4%, s = 0.02% (5 ampoules in duplicate, July 2014)
	Re-analysis:	Mean = 99.3%, s = 0.02% (5 ampoules in duplicate, June 2019)

The following analytical data was obtained on the bulk material subsequently used in the preparation of the ampoules.

The identity was confirmed by a range of spectroscopic techniques, NMR, IR and MS. The certified purity value was obtained by mass balance from a combination of traditional analytical techniques, including GC-FID, thermogravimetric analysis, Karl Fischer analysis and 1 H NMR spectroscopy. The purity value is calculated as per Equation 1

$$\text{Purity} = (100\% - I_{\text{ORG}}) \times (100\% - I_{\text{VOL}} - I_{\text{NVR}}) \quad \text{Equation 1}$$

I_{ORG} = Organic impurities of related structure, I_{VOL} = volatile impurities, I_{NVR} = non-volatile residue.

Supporting evidence is provided by elemental microanalysis.

GC-FID:	Instrument:	Agilent 6890N
	Column:	HP-1 Capillary, 30 m \times 0.32 mm I.D. \times 0.25 μ m
	Program:	180 $^{\circ}$ C (1 min), 10 $^{\circ}$ C/min to 240 $^{\circ}$ C (3 min), 30 $^{\circ}$ C/min to 300 $^{\circ}$ C (3 min)
	Injector:	250 $^{\circ}$ C
	Detector Temp:	320 $^{\circ}$ C
	Carrier:	Helium
	Split ratio:	20/1
	Relative mass fraction of the main component:	
	Initial analysis:	Mean = 99.5%, s = 0.01% (10 sub samples, March 1999)
	Re-analysis:	Mean = 99.3%, s = 0.03% (5 sub samples in duplicate, August 2008)

Thermogravimetric analysis: Volatiles content < 0.1% and non-volatile residue < 0.2% mass fraction (February 2000 & August 2005)
Volatiles content 0.1% and non-volatile residue < 0.2% mass fraction (August 2008)

Karl Fischer analysis: Moisture content 0.2% mass fraction (August 2008)

Spectroscopic and other characterisation data

GC-MS: Parent compound:
Instrument: HP6890/5973
Columns: HP Ultra 2, 17 m \times 0.22 mm I.D. \times 0.11 μ m
Program: 140 $^{\circ}$ C (1 min), 8 $^{\circ}$ C/min to 250 $^{\circ}$ C, 30 $^{\circ}$ C/min to 300 $^{\circ}$ C (3 min)
Injector: 280 $^{\circ}$ C
Split ratio: Splitless injection
Transfer line temp: 300 $^{\circ}$ C
Carrier: Helium, 1.0 mL/min

Bis-trimethylsilyl derivative:

Instrument: HP6890 / 5973
Column: HP Ultra 1, 17 m \times 0.22 mm I.D. \times 0.11 μ m
Program: 170 $^{\circ}$ C, 3 $^{\circ}$ C/min to 234 $^{\circ}$ C, 10 $^{\circ}$ C/min to 265 $^{\circ}$ C (3 min)
Injector: 280 $^{\circ}$ C
Split ratio: 15/1
Transfer line temp: 300 $^{\circ}$ C
Carrier: Helium

The retention time of the parent compound and its *bis*-TMS derivative are reported with the major peaks observed in the mass spectra. The latter are reported as mass/charge ratios and (in brackets) as a percentage relative to the base peak.

Parent (7.6 min): 302 (M^+ -H₂O, 86), 287 (71), 284 (60), 269 (100), 260 (44), 229 (83) *m/z*

Bis-TMS (12.0 min): 449 (M^+ -CH₃, 1), 374 (3), 284 (7), 269 (5), 242 (5), 229 (7), 143 (100) *m/z*

TLC: Conditions: Kieselgel 60F₂₅₄. Hexane/ethyl acetate (60:40)
Single spot observed, R_f = 0.25 (5 samples)

IR: Instrument: FT-IR, Biorad WIN FTS40
Range: 4000-400 cm⁻¹, KBr pellet
Peaks: 3596, 3474, 1448, 1385, 1289, 1097, 1072, 933 cm⁻¹

¹H NMR: Instrument: Bruker Advance-300
Field strength: 300 MHz
Solvent: CDCl₃ (77.5 ppm)
Spectral data: δ 0.81 (3H, s), 0.93 (3H, s), 0.98 (3H, d), 3.45 (1H, m) ppm

¹³C NMR: Instrument: Bruker Advance-300
Field strength: 75 MHz
Solvent: CDCl₃ (77.5 ppm)
Spectral data: δ 13.6, 18.1, 20.3, 23.1, 23.2, 25.8, 29.1, 30.7, 31.5, 33.0, 34.6, 35.5, 35.6, 38.3, 38.8, 40.2, 42.5, 45.3, 45.9, 71.9, 81.6 ppm

Melting point: 196-198 $^{\circ}$ C

Microanalysis: Found: C = 78.8%, H = 11.3% (November 1999)
Calculated: C = 78.7%, H = 11.3% (Calculated for C₂₁H₃₆O₂)